BioMarin commences Phase 3b study of Kuvan’s neuropsychiatric effects in phenylketonuria patients
BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). BioMarin expects to report results in the first half of 2012.

Read more on News-Medical-Net

Malema Wants ANC Leadership Changes by 2012, Sunday Independent Reports
The ANC needs a leadership that will represent the views of the poor and younger generations within the party, the Johannesburg-based newspaper cited Malema as saying yesterday at a conference of the youth league’s Gauteng branch.

Read more on Bloomberg